# Specialized Cancer Types

This section provides underwriting guidelines for rare and specialized cancer types that require specific risk assessment approaches due to their unique clinical characteristics, treatment modalities, and prognosis profiles.

## Neuroendocrine Tumors (NETs)

**Definition**: A heterogeneous group of neoplasms that arise from cells of the endocrine and nervous systems, most commonly occurring in the gastrointestinal tract, pancreas, and lungs.

### Classification

#### WHO Grading System
- **Grade 1 (G1)**: Ki-67 index <3%; <2 mitoses/10 HPF
- **Grade 2 (G2)**: Ki-67 index 3-20%; 2-20 mitoses/10 HPF
- **Grade 3 (G3)**: Ki-67 index >20%; >20 mitoses/10 HPF
  - Well-differentiated NET G3
  - Poorly differentiated neuroendocrine carcinoma (NEC)

#### Primary Site Classification
- Gastroenteropancreatic NETs (GEP-NETs)
  - Pancreatic NETs (pNETs)
  - Gastrointestinal NETs (carcinoids)
- Lung NETs (typical and atypical carcinoids)
- Thymic NETs
- Other sites (adrenal, skin, genital tract, etc.)

### Required Evidence

1. **Minimum Documentation**:
   - Pathology report with WHO grade
   - Ki-67 proliferation index
   - Mitotic count
   - Differentiation status
   - Primary site location
   - Tumor size
   - Imaging studies (CT, MRI, somatostatin receptor imaging)
   - Biomarker levels (Chromogranin A, 5-HIAA, specific hormones)
   - Surgical reports (if applicable)
   - Documentation of functional status
   - TNM staging information
   - Treatment history and response

2. **Additional Evidence for Complex Cases**:
   - Genetic testing (MEN1, VHL, etc.)
   - Gallium-68 DOTATATE PET scan results
   - RECIST or PRRT response assessments
   - Carcinoid syndrome assessment
   - Echocardiogram (if carcinoid syndrome present)

### Underwriting Guidelines

#### Well-Differentiated NETs (G1/G2)

| Stage | Grade | Resection Status | Time Since Diagnosis | Rating |
|-------|-------|-----------------|---------------------|--------|
| **I** | G1 | Complete resection | <12 months | Table 3-5 |
| **I** | G1 | Complete resection | 12-36 months | Table 2-4 |
| **I** | G1 | Complete resection | >36 months | Table 1-3 |
| **I** | G2 | Complete resection | <12 months | Table 4-6 |
| **I** | G2 | Complete resection | 12-36 months | Table 3-5 |
| **I** | G2 | Complete resection | >36 months | Table 2-4 |
| **II** | G1 | Complete resection | <12 months | Table 4-6 |
| **II** | G1 | Complete resection | 12-36 months | Table 3-5 |
| **II** | G1 | Complete resection | >36 months | Table 2-4 |
| **II** | G2 | Complete resection | <12 months | Table 5-7 |
| **II** | G2 | Complete resection | 12-36 months | Table 4-6 |
| **II** | G2 | Complete resection | >36 months | Table 3-5 |
| **III** | G1/G2 | Complete resection | <24 months | Table 6-8 |
| **III** | G1/G2 | Complete resection | 24-60 months | Table 5-7 |
| **III** | G1/G2 | Complete resection | >60 months | Table 4-6 |
| **IV** | G1 | Any | <24 months | Table 7-9 |
| **IV** | G1 | Any | 24-60 months | Table 6-8 |
| **IV** | G1 | Any | >60 months | Table 5-7 |
| **IV** | G2 | Any | <36 months | Table 8-10 |
| **IV** | G2 | Any | 36-60 months | Table 7-9 |
| **IV** | G2 | Any | >60 months | Table 6-8 |

#### G3 NETs and Neuroendocrine Carcinomas (NECs)

| Type | Stage | Time Since Diagnosis | Rating |
|------|-------|---------------------|--------|
| **Well-diff G3 NET** | I-III | <36 months | Table 6-8 |
| **Well-diff G3 NET** | I-III | 36-60 months | Table 5-7 |
| **Well-diff G3 NET** | I-III | >60 months | Table 4-6 |
| **Well-diff G3 NET** | IV | <36 months | Table 8+ or Postpone |
| **Well-diff G3 NET** | IV | 36-60 months | Table 7-9 |
| **Well-diff G3 NET** | IV | >60 months | Table 6-8 |
| **Poorly-diff NEC** | I-III | <36 months | Table 8+ or Postpone |
| **Poorly-diff NEC** | I-III | 36-60 months | Table 7-9 |
| **Poorly-diff NEC** | I-III | >60 months | Table 6-8 |
| **Poorly-diff NEC** | IV | <60 months | Postpone or Decline |
| **Poorly-diff NEC** | IV | >60 months | Individual consideration |

**Modifying Factors**:
- Carcinoid syndrome present: +1 table
- Carcinoid heart disease: +2 tables
- Multiple endocrine neoplasia syndrome: +1 table
- Stable disease on somatostatin analogs >3 years: -1 table
- Liver metastases with >50% involvement: +1 table
- Multiple sites of metastatic disease: +1 table
- Functional tumor with hormone production: +1 table
- Complete response to PRRT: -1 table
- Hereditary syndrome (MEN1, VHL): +1 table

## Gastrointestinal Stromal Tumors (GISTs)

**Definition**: Mesenchymal tumors that arise from the interstitial cells of Cajal in the gastrointestinal tract, most commonly occurring in the stomach and small intestine.

### Risk Classification

#### Modified NIH Consensus Criteria (Risk of Recurrence)
- **Very low risk**: Tumor size <2 cm, mitotic index <5/50 HPF
- **Low risk**: Tumor size 2-5 cm, mitotic index <5/50 HPF
- **Intermediate risk**: 
  - Tumor size <5 cm, mitotic index 6-10/50 HPF, or
  - Tumor size 5-10 cm, mitotic index <5/50 HPF
- **High risk**: 
  - Tumor size >10 cm, any mitotic index, or
  - Tumor size >5 cm, mitotic index >5/50 HPF, or
  - Any size, mitotic index >10/50 HPF, or
  - Tumor rupture

### Required Evidence

1. **Minimum Documentation**:
   - Pathology report with mitotic index
   - Tumor size and location
   - Immunohistochemistry (CD117/KIT, DOG1)
   - Mutation analysis (KIT, PDGFRA)
   - Surgical details including margin status
   - Treatment history (including TKIs)
   - Recurrence history
   - Most recent imaging studies

2. **Additional Evidence**:
   - Response assessment to TKI therapy
   - Surveillance protocol adherence
   - Documentation of resistance mutations

### Underwriting Guidelines

| Risk Category | Treatment Status | Time Since Diagnosis | Rating |
|---------------|-----------------|---------------------|--------|
| **Very low** | Surgical resection only | <12 months | Table 2-4 |
| **Very low** | Surgical resection only | 12-36 months | Table 1-3 |
| **Very low** | Surgical resection only | >36 months | Standard to Table 2 |
| **Low** | Surgical resection only | <12 months | Table 3-5 |
| **Low** | Surgical resection only | 12-36 months | Table 2-4 |
| **Low** | Surgical resection only | >36 months | Table 1-3 |
| **Intermediate** | Complete resection | <24 months | Table 4-6 |
| **Intermediate** | Complete resection | 24-60 months | Table 3-5 |
| **Intermediate** | Complete resection | >60 months | Table 2-4 |
| **High** | Complete resection + adjuvant imatinib | <24 months | Table 5-7 |
| **High** | Complete resection + adjuvant imatinib | 24-60 months | Table 4-6 |
| **High** | Complete resection + adjuvant imatinib | >60 months | Table 3-5 |
| **Localized, any risk** | R1/R2 resection | <24 months | Add 1 table to above |
| **Metastatic/Recurrent** | Responsive to TKI | <24 months | Table 6-8 |
| **Metastatic/Recurrent** | Responsive to TKI | 24-60 months | Table 5-7 |
| **Metastatic/Recurrent** | Responsive to TKI | >60 months | Table 4-6 |
| **Metastatic/Recurrent** | Multiple TKI resistance | <36 months | Table 8+ or Postpone |
| **Metastatic/Recurrent** | Multiple TKI resistance | >36 months | Table 7-9 |

**Modifying Factors**:
- KIT exon 11 deletion mutation: -1 table
- PDGFRA D842V mutation: -1 table (imatinib resistance but generally indolent)
- SDH-deficient GIST: +1 table
- Wild-type KIT/PDGFRA: +1 table
- Tumor rupture at presentation: +2 tables
- Extended adjuvant imatinib (>3 years): -1 table
- Discontinuation of adjuvant therapy before 3 years: +1 table

## Sarcomas

**Definition**: A diverse group of rare malignant tumors that arise from mesenchymal cells, which can occur in soft tissues, bones, and visceral organs.

### Classification

#### Histologic Types (Common Examples)
- Soft Tissue Sarcomas
  - Liposarcoma (well-differentiated, dedifferentiated, myxoid, pleomorphic)
  - Leiomyosarcoma
  - Undifferentiated pleomorphic sarcoma
  - Synovial sarcoma
  - Malignant peripheral nerve sheath tumor
  - Angiosarcoma
  - Rhabdomyosarcoma
- Bone Sarcomas
  - Osteosarcoma
  - Ewing sarcoma
  - Chondrosarcoma

#### FNCLCC Grading System
- **Grade 1**: Well-differentiated, low risk
- **Grade 2**: Moderately differentiated, intermediate risk
- **Grade 3**: Poorly differentiated, high risk

### Required Evidence

1. **Minimum Documentation**:
   - Pathology report with histologic type and grade
   - Tumor size, depth, and location
   - Margin status after resection
   - AJCC staging
   - Treatment details (surgery, radiation, chemotherapy)
   - Response to neoadjuvant therapy (if applicable)
   - Imaging studies
   - Recurrence history

2. **Additional Evidence**:
   - Molecular/genetic testing results
   - Functional status assessment
   - Limb salvage vs. amputation details
   - Reconstructive procedures

### Underwriting Guidelines for Soft Tissue Sarcomas

| Stage | Grade | Status | Time Since Diagnosis | Rating |
|-------|-------|--------|---------------------|--------|
| **I** | 1 | Complete resection | <12 months | Table 3-5 |
| **I** | 1 | Complete resection | 12-36 months | Table 2-4 |
| **I** | 1 | Complete resection | >36 months | Table 1-3 |
| **II** | 2 | Complete resection | <24 months | Table 5-7 |
| **II** | 2 | Complete resection | 24-60 months | Table 4-6 |
| **II** | 2 | Complete resection | >60 months | Table 3-5 |
| **III** | 2-3 | Complete resection | <24 months | Table 6-8 |
| **III** | 2-3 | Complete resection | 24-60 months | Table 5-7 |
| **III** | 2-3 | Complete resection | >60 months | Table 4-6 |
| **IV** | Any | NED after treatment | <36 months | Table 8-10 |
| **IV** | Any | NED after treatment | 36-60 months | Table 7-9 |
| **IV** | Any | NED after treatment | >60 months | Table 6-8 |
| **Any** | Any | Recurrent disease | <36 months | Table 8+ or Postpone |
| **Any** | Any | Recurrent disease | >36 months | Table 7-9 |

### Underwriting Guidelines for Specific Sarcoma Types

| Sarcoma Type | Stage | Time Since Diagnosis | Rating |
|--------------|-------|---------------------|--------|
| **Well-differentiated liposarcoma** | Localized | <12 months | Table 3-5 |
| **Well-differentiated liposarcoma** | Localized | 12-36 months | Table 2-4 |
| **Well-differentiated liposarcoma** | Localized | >36 months | Table 1-3 |
| **Myxoid liposarcoma** | Localized | <24 months | Table 4-6 |
| **Myxoid liposarcoma** | Localized | 24-60 months | Table 3-5 |
| **Myxoid liposarcoma** | Localized | >60 months | Table 2-4 |
| **Dedifferentiated/Pleomorphic liposarcoma** | Any | <36 months | Table 6-8 |
| **Dedifferentiated/Pleomorphic liposarcoma** | Any | 36-60 months | Table 5-7 |
| **Dedifferentiated/Pleomorphic liposarcoma** | Any | >60 months | Table 4-6 |
| **Leiomyosarcoma** | I-II | <24 months | Table 5-7 |
| **Leiomyosarcoma** | I-II | 24-60 months | Table 4-6 |
| **Leiomyosarcoma** | I-II | >60 months | Table 3-5 |
| **Leiomyosarcoma** | III-IV | <60 months | Table 7-9 |
| **Leiomyosarcoma** | III-IV | >60 months | Table 6-8 |
| **Angiosarcoma** | Any | <36 months | Table 7-9 |
| **Angiosarcoma** | Any | 36-60 months | Table 6-8 |
| **Angiosarcoma** | Any | >60 months | Table 5-7 |
| **Synovial sarcoma** | I-II | <36 months | Table 6-8 |
| **Synovial sarcoma** | I-II | 36-60 months | Table 5-7 |
| **Synovial sarcoma** | I-II | >60 months | Table 4-6 |
| **Osteosarcoma** | Non-metastatic | <36 months | Table 6-8 |
| **Osteosarcoma** | Non-metastatic | 36-60 months | Table 5-7 |
| **Osteosarcoma** | Non-metastatic | >60 months | Table 4-6 |
| **Ewing sarcoma** | Localized | <36 months | Table 6-8 |
| **Ewing sarcoma** | Localized | 36-60 months | Table 5-7 |
| **Ewing sarcoma** | Localized | >60 months | Table 4-6 |
| **Chondrosarcoma (G1)** | I | <24 months | Table 3-5 |
| **Chondrosarcoma (G1)** | I | >24 months | Table 2-4 |
| **Chondrosarcoma (G2-3)** | II-III | <36 months | Table 5-7 |
| **Chondrosarcoma (G2-3)** | II-III | >36 months | Table 4-6 |

**Modifying Factors**:
- Size >10 cm at diagnosis: +1 table
- Deep location (not subcutaneous): +1 table
- Positive surgical margins: +1 table
- Local recurrence history: +1 table
- Radiation-associated sarcoma: +1 table
- Sarcoma in patient with genetic predisposition syndrome: +1 table
- Chemotherapy response >90% necrosis: -1 table
- Limb amputation: No additional rating
- Retroperitoneal location: +1 table

## Primary Central Nervous System Tumors

**Definition**: Tumors that originate in the brain, spinal cord, or the coverings of these organs (meninges), including various histologic types with diverse biological behavior.

### Classification

#### WHO Classification of CNS Tumors (2021)
- Based on both histology and molecular features
- Incorporates specific genetic alterations

#### Major Categories
- Diffuse gliomas
  - Astrocytoma, IDH-mutant
  - Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
  - Glioblastoma, IDH-wildtype
- Other astrocytic tumors
  - Pilocytic astrocytoma
  - Pleomorphic xanthoastrocytoma
- Ependymal tumors
- Choroid plexus tumors
- Neuronal and mixed neuronal-glial tumors
- Embryonal tumors (e.g., medulloblastoma)
- Meningiomas
- Schwannomas and neurofibromas
- Primary CNS lymphomas
- Germ cell tumors
- Tumors of the sellar region (e.g., pituitary adenomas, craniopharyngiomas)

### Required Evidence

1. **Minimum Documentation**:
   - Pathology report with WHO grade
   - Molecular testing results (IDH, 1p/19q, MGMT, etc.)
   - Imaging studies (MRI, spectroscopy if available)
   - Treatment details (surgery, radiation, chemotherapy)
   - Residual tumor assessment
   - Neurological status and functional assessment
   - Seizure history and control
   - Recurrence history

2. **Additional Evidence**:
   - Neurocognitive assessment
   - Performance status (KPS or ECOG)
   - Steroid requirements
   - CSF cytology for leptomeningeal disease

### Underwriting Guidelines for Diffuse Gliomas

| Tumor Type | WHO Grade | Treatment Status | Time Since Diagnosis | Rating |
|------------|-----------|-----------------|---------------------|--------|
| **Astrocytoma, IDH-mutant** | 2 | Gross total resection | <24 months | Table 5-7 |
| **Astrocytoma, IDH-mutant** | 2 | Gross total resection | 24-60 months | Table 4-6 |
| **Astrocytoma, IDH-mutant** | 2 | Gross total resection | >60 months | Table 3-5 |
| **Astrocytoma, IDH-mutant** | 3 | Complete treatment | <36 months | Table 7-9 |
| **Astrocytoma, IDH-mutant** | 3 | Complete treatment | 36-60 months | Table 6-8 |
| **Astrocytoma, IDH-mutant** | 3 | Complete treatment | >60 months | Table 5-7 |
| **Oligodendroglioma, IDH-mutant, 1p/19q-codeleted** | 2 | Gross total resection | <24 months | Table 4-6 |
| **Oligodendroglioma, IDH-mutant, 1p/19q-codeleted** | 2 | Gross total resection | 24-60 months | Table 3-5 |
| **Oligodendroglioma, IDH-mutant, 1p/19q-codeleted** | 2 | Gross total resection | >60 months | Table 2-4 |
| **Oligodendroglioma, IDH-mutant, 1p/19q-codeleted** | 3 | Complete treatment | <36 months | Table 6-8 |
| **Oligodendroglioma, IDH-mutant, 1p/19q-codeleted** | 3 | Complete treatment | 36-60 months | Table 5-7 |
| **Oligodendroglioma, IDH-mutant, 1p/19q-codeleted** | 3 | Complete treatment | >60 months | Table 4-6 |
| **Glioblastoma, IDH-wildtype** | 4 | Complete treatment | <24 months | Table 8+ or Decline |
| **Glioblastoma, IDH-wildtype** | 4 | Complete treatment | 24-36 months | Table 8-10 |
| **Glioblastoma, IDH-wildtype** | 4 | Complete treatment | 36-60 months | Table 7-9 |
| **Glioblastoma, IDH-wildtype** | 4 | Complete treatment | >60 months | Table 6-8 |
| **Any diffuse glioma** | Any | Subtotal resection | Add 1 table to above | |
| **Any diffuse glioma** | Any | Recurrent disease | <24 months | Postpone or Decline |

### Underwriting Guidelines for Non-Diffuse Gliomas and Other CNS Tumors

| Tumor Type | WHO Grade | Treatment Status | Time Since Diagnosis | Rating |
|------------|-----------|-----------------|---------------------|--------|
| **Pilocytic astrocytoma** | 1 | Gross total resection | <12 months | Table 3-5 |
| **Pilocytic astrocytoma** | 1 | Gross total resection | 12-36 months | Table 2-4 |
| **Pilocytic astrocytoma** | 1 | Gross total resection | >36 months | Table 1-3 |
| **Ependymoma** | 2 | Gross total resection | <24 months | Table 4-6 |
| **Ependymoma** | 2 | Gross total resection | 24-60 months | Table 3-5 |
| **Ependymoma** | 2 | Gross total resection | >60 months | Table 2-4 |
| **Ependymoma** | 3 | Complete treatment | <36 months | Table 6-8 |
| **Ependymoma** | 3 | Complete treatment | 36-60 months | Table 5-7 |
| **Ependymoma** | 3 | Complete treatment | >60 months | Table 4-6 |
| **Medulloblastoma** | 4 | Complete treatment, average risk | <36 months | Table 6-8 |
| **Medulloblastoma** | 4 | Complete treatment, average risk | 36-60 months | Table 5-7 |
| **Medulloblastoma** | 4 | Complete treatment, average risk | >60 months | Table 4-6 |

### Underwriting Guidelines for Meningiomas and Schwannomas

| Tumor Type | WHO Grade | Treatment Status | Time Since Diagnosis | Rating |
|------------|-----------|-----------------|---------------------|--------|
| **Meningioma** | 1 | Complete resection | <12 months | Table 2-4 |
| **Meningioma** | 1 | Complete resection | 12-36 months | Table 1-2 |
| **Meningioma** | 1 | Complete resection | >36 months | Standard to Table 1 |
| **Meningioma** | 1 | Subtotal resection/observation | <12 months | Table 3-5 |
| **Meningioma** | 1 | Subtotal resection/observation | 12-36 months | Table 2-4 |
| **Meningioma** | 1 | Subtotal resection/observation | >36 months | Table 1-3 |
| **Meningioma** | 2 | Complete resection | <24 months | Table 4-6 |
| **Meningioma** | 2 | Complete resection | 24-60 months | Table 3-5 |
| **Meningioma** | 2 | Complete resection | >60 months | Table 2-4 |
| **Meningioma** | 3 | Complete treatment | <36 months | Table 6-8 |
| **Meningioma** | 3 | Complete treatment | 36-60 months | Table 5-7 |
| **Meningioma** | 3 | Complete treatment | >60 months | Table 4-6 |
| **Vestibular schwannoma** | 1 | Any treatment | <12 months | Table 2-4 |
| **Vestibular schwannoma** | 1 | Any treatment | 12-36 months | Table 1-3 |
| **Vestibular schwannoma** | 1 | Any treatment | >36 months | Standard to Table 2 |

**Modifying Factors**:
- MGMT promoter methylation in glioblastoma: -1 table
- IDH-wildtype in grade 2-3 astrocytoma: +1 table
- Multiple craniotomies: +1 table
- Persistent seizures: +1 table
- Significant neurocognitive impairment: +1 to 2 tables
- Steroid dependence: +1 table
- Molecular features suggesting favorable prognosis: -1 table
- Radiation-induced CNS tumor: +2 tables
- Neurofibromatosis or other genetic predisposition: +1 table
- Age <40 years at diagnosis (for glioblastoma): -1 table

## Germ Cell Tumors

**Definition**: Tumors derived from germ cells, primarily occurring in the gonads (testes or ovaries) but can also develop in extragonadal sites (mediastinum, retroperitoneum, pineal gland, etc.).

### Classification

#### By Site
- Testicular germ cell tumors
- Ovarian germ cell tumors
- Extragonadal germ cell tumors

#### By Histology
- Seminomatous germ cell tumors (seminoma, germinoma, dysgerminoma)
- Non-seminomatous germ cell tumors (NSGCT)
  - Embryonal carcinoma
  - Yolk sac tumor
  - Choriocarcinoma
  - Teratoma (mature, immature, teratoma with malignant transformation)
  - Mixed germ cell tumors

### Required Evidence

1. **Minimum Documentation**:
   - Pathology report with histologic type
   - Tumor markers (AFP, β-hCG, LDH) before and after treatment
   - Staging workup results
   - Surgery details
   - Chemotherapy regimen and response
   - Surveillance protocol adherence
   - Post-treatment imaging
   - Recurrence history
   - International Germ Cell Cancer Collaborative Group (IGCCCG) risk class for advanced disease

2. **Additional Evidence**:
   - Documentation of retroperitoneal lymph node dissection (if performed)
   - Salvage therapy details (if applicable)
   - Fertility status and sperm banking
   - Late treatment effects assessment

### Underwriting Guidelines for Testicular Germ Cell Tumors

| Type | Stage | Treatment | Time Since Diagnosis | Rating |
|------|-------|----------|---------------------|--------|
| **Seminoma** | I | Orchiectomy +/- radiation | <12 months | Table 3-4 |
| **Seminoma** | I | Orchiectomy +/- radiation | 12-36 months | Table 2-3 |
| **Seminoma** | I | Orchiectomy +/- radiation | >36 months | Table 1-2 |
| **Seminoma** | I | Orchiectomy + carboplatin | <12 months | Table 3-4 |
| **Seminoma** | I | Orchiectomy + carboplatin | 12-36 months | Table 2-3 |
| **Seminoma** | I | Orchiectomy + carboplatin | >36 months | Table 1-2 |
| **Seminoma** | II | Complete treatment | <24 months | Table 4-5 |
| **Seminoma** | II | Complete treatment | 24-60 months | Table 3-4 |
| **Seminoma** | II | Complete treatment | >60 months | Table 2-3 |
| **Seminoma** | III, good risk | Complete treatment | <24 months | Table 5-6 |
| **Seminoma** | III, good risk | Complete treatment | 24-60 months | Table 4-5 |
| **Seminoma** | III, good risk | Complete treatment | >60 months | Table 3-4 |
| **Seminoma** | III, intermediate risk | Complete treatment | <36 months | Table 6-7 |
| **Seminoma** | III, intermediate risk | Complete treatment | 36-60 months | Table 5-6 |
| **Seminoma** | III, intermediate risk | Complete treatment | >60 months | Table 4-5 |
| **NSGCT** | I | Orchiectomy only | <12 months | Table 4-5 |
| **NSGCT** | I | Orchiectomy only | 12-36 months | Table 3-4 |
| **NSGCT** | I | Orchiectomy only | >36 months | Table 2-3 |
| **NSGCT** | I | Orchiectomy + adjuvant chemo | <12 months | Table 4-5 |
| **NSGCT** | I | Orchiectomy + adjuvant chemo | 12-36 months | Table 3-4 |
| **NSGCT** | I | Orchiectomy + adjuvant chemo | >36 months | Table 2-3 |
| **NSGCT** | II-III, good risk | Complete treatment | <24 months | Table 5-6 |
| **NSGCT** | II-III, good risk | Complete treatment | 24-60 months | Table 4-5 |
| **NSGCT** | II-III, good risk | Complete treatment | >60 months | Table 3-4 |
| **NSGCT** | II-III, intermediate risk | Complete treatment | <36 months | Table 6-7 |
| **NSGCT** | II-III, intermediate risk | Complete treatment | 36-60 months | Table 5-6 |
| **NSGCT** | II-III, intermediate risk | Complete treatment | >60 months | Table 4-5 |
| **NSGCT** | III, poor risk | Complete treatment | <36 months | Table 7-8 |
| **NSGCT** | III, poor risk | Complete treatment | 36-60 months | Table 6-7 |
| **NSGCT** | III, poor risk | Complete treatment | >60 months | Table 5-6 |
| **Any GCT** | Any | Recurrence, salvage therapy | <36 months | Table 7-9 |
| **Any GCT** | Any | Recurrence, salvage therapy | 36-60 months | Table 6-8 |
| **Any GCT** | Any | Recurrence, salvage therapy | >60 months | Table 5-7 |

### Underwriting Guidelines for Ovarian Germ Cell Tumors

| Type | Stage | Treatment | Time Since Diagnosis | Rating |
|------|-------|----------|---------------------|--------|
| **Dysgerminoma** | I | Fertility-sparing surgery | <12 months | Table 3-4 |
| **Dysgerminoma** | I | Fertility-sparing surgery | 12-36 months | Table 2-3 |
| **Dysgerminoma** | I | Fertility-sparing surgery | >36 months | Table 1-2 |
| **Dysgerminoma** | II-III | Complete treatment | <24 months | Table 5-6 |
| **Dysgerminoma** | II-III | Complete treatment | 24-60 months | Table 4-5 |
| **Dysgerminoma** | II-III | Complete treatment | >60 months | Table 3-4 |
| **Immature teratoma** | I, grade 1 | Fertility-sparing surgery | <12 months | Table 3-4 |
| **Immature teratoma** | I, grade 1 | Fertility-sparing surgery | 12-36 months | Table 2-3 |
| **Immature teratoma** | I, grade 1 | Fertility-sparing surgery | >36 months | Table 1-2 |
| **Immature teratoma** | I, grade 2-3 | Complete treatment | <24 months | Table 4-5 |
| **Immature teratoma** | I, grade 2-3 | Complete treatment | 24-60 months | Table 3-4 |
| **Immature teratoma** | I, grade 2-3 | Complete treatment | >60 months | Table 2-3 |
| **Other NSGCT** | I-II | Complete treatment | <24 months | Table 5-6 |
| **Other NSGCT** | I-II | Complete treatment | 24-60 months | Table 4-5 |
| **Other NSGCT** | I-II | Complete treatment | >60 months | Table 3-4 |
| **Any type** | III-IV | Complete treatment | <36 months | Table 6-7 |
| **Any type** | III-IV | Complete treatment | 36-60 months | Table 5-6 |
| **Any type** | III-IV | Complete treatment | >60 months | Table 4-5 |

### Underwriting Guidelines for Extragonadal Germ Cell Tumors

| Type | Site | Treatment | Time Since Diagnosis | Rating |
|------|------|----------|---------------------|--------|
| **Seminoma** | Mediastinum | Complete treatment | <36 months | Table 5-7 |
| **Seminoma** | Mediastinum | Complete treatment | 36-60 months | Table 4-6 |
| **Seminoma** | Mediastinum | Complete treatment | >60 months | Table 3-5 |
| **Seminoma** | Retroperitoneum | Complete treatment | <36 months | Table 5-7 |
| **Seminoma** | Retroperitoneum | Complete treatment | 36-60 months | Table 4-6 |
| **Seminoma** | Retroperitoneum | Complete treatment | >60 months | Table 3-5 |
| **NSGCT** | Mediastinum | Complete treatment | <36 months | Table 7-9 |
| **NSGCT** | Mediastinum | Complete treatment | 36-60 months | Table 6-8 |
| **NSGCT** | Mediastinum | Complete treatment | >60 months | Table 5-7 |
| **NSGCT** | Retroperitoneum | Complete treatment | <36 months | Table 6-8 |
| **NSGCT** | Retroperitoneum | Complete treatment | 36-60 months | Table 5-7 |
| **NSGCT** | Retroperitoneum | Complete treatment | >60 months | Table 4-6 |
| **Germinoma** | CNS | Complete treatment | <36 months | Table 6-8 |
| **Germinoma** | CNS | Complete treatment | 36-60 months | Table 5-7 |
| **Germinoma** | CNS | Complete treatment | >60 months | Table 4-6 |
| **NSGCT** | CNS | Complete treatment | <36 months | Table 7-9 |
| **NSGCT** | CNS | Complete treatment | 36-60 months | Table 6-8 |
| **NSGCT** | CNS | Complete treatment | >60 months | Table 5-7 |

**Modifying Factors**:
- Normalized tumor markers post-treatment: -1 table
- Residual mass post-chemotherapy (teratoma): No additional rating
- Secondary hematologic malignancies: +2 tables
- Bleomycin pulmonary toxicity: +1 to 2 tables
- Embryonal carcinoma component >40%: +1 table
- Choriocarcinoma component: +1 table
- Full surveillance compliance: -1 table
- High-dose chemotherapy with stem cell support: +1 table
- Contralateral testicular GCT: +1 table

## Merkel Cell Carcinoma

**Definition**: A rare, aggressive cutaneous neuroendocrine carcinoma that typically presents as a rapidly growing, painless, red-to-violet nodule, most commonly on sun-exposed areas.

### Risk Factors
- Merkel cell polyomavirus (MCPyV) infection (80% of cases)
- Ultraviolet radiation exposure
- Immunosuppression
- Advanced age (>65 years)

### Required Evidence

1. **Minimum Documentation**:
   - Pathology report with confirmation of diagnosis
   - Immunohistochemistry results (CK20, TTF-1, etc.)
   - Primary tumor characteristics (size, depth, lymphovascular invasion)
   - Sentinel lymph node biopsy results
   - Imaging studies (CT, PET/CT)
   - Complete treatment history
   - Recurrence history
   - Ongoing surveillance protocol

2. **Additional Evidence**:
   - MCPyV status (if tested)
   - PD-L1 expression (if tested)
   - Immune checkpoint inhibitor response data

### Underwriting Guidelines

| Stage | Treatment | Time Since Diagnosis | Rating |
|-------|----------|---------------------|--------|
| **I (≤2cm, node-negative)** | Complete treatment | <12 months | Table 5-7 |
| **I (≤2cm, node-negative)** | Complete treatment | 12-36 months | Table 4-6 |
| **I (≤2cm, node-negative)** | Complete treatment | >36 months | Table 3-5 |
| **IIA/B (>2cm, node-negative)** | Complete treatment | <24 months | Table 6-8 |
| **IIA/B (>2cm, node-negative)** | Complete treatment | 24-60 months | Table 5-7 |
| **IIA/B (>2cm, node-negative)** | Complete treatment | >60 months | Table 4-6 |
| **III (node-positive)** | Complete treatment | <24 months | Table 7-9 |
| **III (node-positive)** | Complete treatment | 24-60 months | Table 6-8 |
| **III (node-positive)** | Complete treatment | >60 months | Table 5-7 |
| **IV (metastatic)** | Complete response to treatment | <36 months | Table 8-10 |
| **IV (metastatic)** | Complete response to treatment | 36-60 months | Table 7-9 |
| **IV (metastatic)** | Complete response to treatment | >60 months | Table 6-8 |
| **Any stage** | Recurrent disease | <36 months | Table 8+ or Postpone |
| **Any stage** | Recurrent disease | >36 months | Table 7-9 |

**Modifying Factors**:
- Immunosuppressed status: +2 tables
- MCPyV-negative tumor: +1 table
- Head and neck primary: +1 table
- Response to immune checkpoint inhibitors: -1 table
- Multiple primary lesions: +1 table

## Rare Gynecologic Malignancies

This section covers selected rare gynecologic cancers that require specialized underwriting considerations.

### Vulvar Cancer

**Definition**: A rare malignancy of the vulva, most commonly squamous cell carcinoma, affecting primarily postmenopausal women.

#### Underwriting Guidelines for Vulvar Cancer

| Stage | Treatment | Time Since Diagnosis | Rating |
|-------|----------|---------------------|--------|
| **I** | Complete resection | <12 months | Table 4-6 |
| **I** | Complete resection | 12-36 months | Table 3-5 |
| **I** | Complete resection | >36 months | Table 2-4 |
| **II** | Complete treatment | <24 months | Table 5-7 |
| **II** | Complete treatment | 24-60 months | Table 4-6 |
| **II** | Complete treatment | >60 months | Table 3-5 |
| **III** | Complete treatment | <36 months | Table 6-8 |
| **III** | Complete treatment | 36-60 months | Table 5-7 |
| **III** | Complete treatment | >60 months | Table 4-6 |
| **IVA/B** | Complete treatment | <36 months | Table 7-9 |
| **IVA/B** | Complete treatment | 36-60 months | Table 6-8 |
| **IVA/B** | Complete treatment | >60 months | Table 5-7 |

**Modifying Factors**:
- HPV-related disease: -1 table
- Perineural invasion: +1 table
- Close or positive margins: +1 table
- Lymphovascular invasion: +1 table
- Multiple recurrences: +2 tables
- Immunosuppression: +1 table

### Vaginal Cancer

**Definition**: A rare malignancy arising from the vaginal epithelium, most commonly squamous cell carcinoma, accounting for 1-2% of gynecologic malignancies.

#### Underwriting Guidelines for Vaginal Cancer

| Stage | Treatment | Time Since Diagnosis | Rating |
|-------|----------|---------------------|--------|
| **I** | Complete treatment | <24 months | Table 5-7 |
| **I** | Complete treatment | 24-60 months | Table 4-6 |
| **I** | Complete treatment | >60 months | Table 3-5 |
| **II** | Complete treatment | <24 months | Table 6-8 |
| **II** | Complete treatment | 24-60 months | Table 5-7 |
| **II** | Complete treatment | >60 months | Table 4-6 |
| **III/IVA** | Complete treatment | <36 months | Table 7-9 |
| **III/IVA** | Complete treatment | 36-60 months | Table 6-8 |
| **III/IVA** | Complete treatment | >60 months | Table 5-7 |
| **IVB** | Complete treatment | <36 months | Table 8-10 or Postpone |
| **IVB** | Complete treatment | >36 months | Table 7-9 |

**Modifying Factors**:
- Clear cell or melanoma histology: +1 table
- HPV-related disease: -1 table
- Prior pelvic radiation exposure: +1 table
- DES exposure in utero: No additional rating

### Gestational Trophoblastic Neoplasia (GTN)

**Definition**: A group of rare tumors that form from trophoblastic tissue after fertilization, including hydatidiform mole, invasive mole, choriocarcinoma, and placental site trophoblastic tumor.

#### Underwriting Guidelines for GTN

| Type | FIGO Score | Time Since Diagnosis | Rating |
|------|-----------|---------------------|--------|
| **Complete hydatidiform mole** | N/A | <12 months | Table 3-4 |
| **Complete hydatidiform mole** | N/A | >12 months | Table 1-2 |
| **Low-risk GTN** | 0-6 | <12 months | Table 4-5 |
| **Low-risk GTN** | 0-6 | 12-24 months | Table 3-4 |
| **Low-risk GTN** | 0-6 | >24 months | Table 2-3 |
| **High-risk GTN** | ≥7 | <24 months | Table 5-6 |
| **High-risk GTN** | ≥7 | 24-60 months | Table 4-5 |
| **High-risk GTN** | ≥7 | >60 months | Table 3-4 |
| **PSTT/ETT** | Any | <36 months | Table 6-7 |
| **PSTT/ETT** | Any | 36-60 months | Table 5-6 |
| **PSTT/ETT** | Any | >60 months | Table 4-5 |

**Modifying Factors**:
- Brain metastases (resolved): +1 table
- Multiple courses of chemotherapy: +1 table
- Normalized β-hCG for >12 months: -1 table
- Subsequent normal pregnancy: -1 table

## Postpone/Decline Criteria

### Postpone

1. Recent diagnosis of specialized cancer (<3-6 months)
2. Active treatment phase for any specialized cancer
3. Pending restaging or disease evaluation
4. Recent surgical resection (<3 months) requiring rehabilitation
5. Unstable or significantly fluctuating tumor markers
6. Brain metastases under active treatment
7. Neurological deficits currently under rehabilitation
8. Recent radiation therapy (<3 months)
9. Recent progressive disease now responding to new treatment (<6 months)
10. Recent serious treatment complication (<3 months)

### Decline

1. Metastatic NET with significant carcinoid syndrome
2. Rapidly progressive high-grade sarcoma
3. Multiple recurrences of specialized cancer within past 24 months
4. Glioblastoma within first 24 months of diagnosis
5. Metastatic Merkel cell carcinoma within first 24 months of diagnosis
6. Poor-risk germ cell tumor with inadequate treatment response
7. Metastatic NET with significant liver involvement (>50%)
8. Active or progressive CNS disease
9. Severe neurological deficits from CNS tumors
10. Multiple specialized cancers with additive poor prognosis features

## Medication Considerations

| Medication Category | Examples | Underwriting Significance |
|--------------------|----------|---------------------------|
| **Somatostatin Analogs** | Octreotide, Lanreotide | Standard NET treatment; well-tolerated; indicates functional tumor |
| **Tyrosine Kinase Inhibitors** | Sunitinib, Pazopanib, Imatinib | Used for various cancers; target-specific; effectiveness varies by tumor type |
| **mTOR Inhibitors** | Everolimus | Used for NETs and other cancers; immunosuppressive properties |
| **PRRT** | Lutetium-177 dotatate | Advanced NET treatment; good efficacy; possible bone marrow toxicity |
| **Platinum-based Chemotherapy** | Cisplatin, Carboplatin | Standard for germ cell tumors; generally curative; long-term toxicity concerns |
| **PD-1/PD-L1 Inhibitors** | Pembrolizumab, Avelumab | Used for Merkel cell and various other cancers; durable responses |
| **Alkylating Agents** | Temozolomide, Lomustine | Used for brain tumors; moderately effective; cumulative toxicity |
| **Capecitabine** | Xeloda | Oral chemotherapy for various tumors; palliative or adjuvant |

## Comorbidity Considerations

The following conditions may increase ratings for specialized cancers:

| Comorbidity | Rating Adjustment |
|-------------|-------------------|
| Secondary malignancy | Rate for both conditions |
| Carcinoid heart disease | +2 to 3 tables |
| Radiation-induced organ damage | +1 to 2 tables |
| Chemotherapy cardiotoxicity | +1 to 2 tables |
| Surgical complications with residual effects | +1 to 2 tables |
| Chronic pain requiring opioids | +1 table |
| Neurocognitive effects from CNS tumors/treatment | +1 to 3 tables |
| Immunosuppression (disease or treatment-related) | +1 to 2 tables |
| Hormone deficiencies requiring replacement | +0 to 1 table |
| Hereditary cancer syndrome | +1 to 2 tables |

## References

1. World Health Organization (WHO) Classifications of Tumors
2. National Comprehensive Cancer Network (NCCN) Guidelines
3. European Society for Medical Oncology (ESMO) Clinical Practice Guidelines
4. European Neuroendocrine Tumor Society (ENETS) Guidelines
5. North American Neuroendocrine Tumor Society (NANETS) Guidelines
6. Surveillance, Epidemiology, and End Results (SEER) Program data
7. American Joint Committee on Cancer (AJCC) TNM Staging
8. International Germ Cell Cancer Collaborative Group (IGCCCG) Risk Classification
9. WHO Classification of CNS Tumors (2021)
10. International Federation of Gynecology and Obstetrics (FIGO) Staging Systems